These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2574192)

  • 1. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 5. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study.
    Perényi A; Arató M; Bagdy G; Frecska E; Szücs R
    J Clin Psychiatry; 1985 Jun; 46(6):229-31. PubMed ID: 2860098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor.
    Metzer WS; Paige SR; Newton JE
    Mov Disord; 1993; 8(1):43-6. PubMed ID: 8093548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia.
    Browne J; Silver H; Martin R; Hart R; Mergener M; Williams P
    J Clin Psychopharmacol; 1986 Apr; 6(2):88-92. PubMed ID: 2871058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
    J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G; Annable L; Ross-Chouinard A; Kropsky ML
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Ringwald E
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tardive dyskinesia: pergolid, a possible therapeutic option].
    Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
    Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia and pseudo-parkinsonism. In a nursing home patient who itched.
    Ondo WG; Hurwitz BJ
    N C Med J; 1993 Nov; 54(11):605-7. PubMed ID: 8272117
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.